Fully automated immunoassay for cholesterol uptake capacity to assess high-density lipoprotein function and

Katsuhiro Murakami1, Amane Harada2, Ryuji Toh3

  • 1Central Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-Ku, Kobe, 651-2271, Japan.

Scientific Reports
|February 2, 2023
PubMed

Insights

A new, rapid assay measures cholesterol uptake capacity (CUC), a key HDL function, offering a faster alternative to traditional methods for assessing cardiovascular health and coronary heart disease risk.

Area of Science:

  • Biochemistry
  • Cardiovascular Science
  • Diagnostic Assays

Background:

  • High-density lipoprotein (HDL) cholesterol efflux capacity (CEC) is linked to coronary heart disease (CHD) risk but requires complex, time-consuming cell-based assays.
  • A cell-free assay for cholesterol uptake capacity (CUC) was previously developed as a novel, more accessible measure of HDL functionality.
  • Clinical application necessitates a rapid, automated, and reproducible assay for CUC measurement.

Purpose of the Study:

  • To develop and validate a rapid, automated, chemiluminescent magnetic particle immunoassay for measuring serum CUC.
  • To assess the correlation of the novel CUC assay with established CEC measurements and clinical outcomes.
  • To evaluate the potential of the CUC assay for cardiovascular risk stratification.

Main Methods:

  • Development of a fully automated chemiluminescent magnetic particle immunoassay for serum CUC measurement.
  • Assessment of CUC in response to HDL modification (myeloperoxidase oxidation, LCAT inhibition/activation).
  • Correlation analysis of CUC with CEC (normalized by ApoA1) and association with coronary revascularization events.

Main Results:

  • The automated assay provides high reproducibility and completes CUC measurement within 20 minutes per sample, significantly faster than CEC assays.
  • CUC levels were sensitive to HDL modifications, decreasing with oxidation or LCAT inhibition and increasing with LCAT activation.
  • Serum CUC correlated with CEC and was significantly associated with the need for revascularization due to recurrent coronary lesions.

Conclusions:

  • A novel, rapid, and automated assay for serum CUC has been successfully developed.
  • This CUC assay serves as a valuable, high-throughput tool for assessing HDL functionality and cardiovascular health.
  • The assay demonstrates potential for accurate risk stratification in patients with coronary artery disease.